Increase of number of shares and votes in Hansa Biopharma AB

Lund, Sweden September 30, 2019. Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that the Company’s registered share capital and number of outstanding shares and votes have increased during the month of September 2019.

As previously announced on 2 September 2019, Hansa Biopharma’s board of directors resolved to issue 715,910 class C shares, by virtue of the authorization by the general meeting held on 22 May 2019 as part of the implementation of the incentive programme LTIP 2019, which was adopted by the annual general meeting held on 22 May 2019. All class C shares are owned by the Company.

As of today, the total number of registered and outstanding shares of Hansa Biopharma amounts to 41,447,564, whereof 40,026,107 are ordinary shares and 1,421,457 are class C shares. As of today, the number of votes in Hansa Biopharma amounts to 40,168,252.7, and the registered share capital amounts to SEK 41,447,564.

For further information, please contact:
Klaus Sindahl, Head of Investor Relations
Hansa Biopharma
Mobile: +46 (0) 709-298 269
E-mail: klaus.sindahl@hansabiopharma.com

Rolf Gulliksen, Head of Corporate Communications
Hansa Biopharma
Mobile: +46 (0) 733-328 634
E-mail: rolf.gulliksen@hansabiopharma.com

About Hansa Biopharma
Hansa Biopharma is leveraging its proprietary immunomodulatory enzyme technology platform to develop treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer. The Company’s lead product, imlifidase, is a unique antibody-degrading enzyme to enable kidney transplantation in highly sensitized patients with potential for further development in other solid organ transplantation and acute autoimmune indications. Imlifidase is currently under potential marketing authorization by EMA. Hansa’s research and development program is advancing the next generation of the Company’s technology to develop novel IgG-cleaving enzymes with lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Biopharma is based in Lund, Sweden and also has operations in the UK and US.